Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 11, 2026
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure:
- Firm Shares: 6,603,449 shares of Common Stock at $58.00 per share.
- Pre-Funded Warrants: 293,103 warrants to purchase Common Stock at $57.9999 per warrant.
- Option Shares: Underwriters exercised a 30-day option in full on February 12, 2026, to purchase an additional 1,034,482 shares.
- Estimated Net Proceeds: Approximately $432.0 million (after underwriting discounts, commissions, and estimated offering expenses).
- Expected Closing Date: February 13, 2026.
- Underwriters: Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co.
Material Changes Versus Prior Period
This filing reports a discrete capital raising event and does not provide comparative financial performance data (e.g., revenue, profit, or cash flow) against a prior period. The primary material change is the anticipated increase in cash liquidity and the dilution of existing shareholders due to the issuance of new shares and warrants.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release (Exhibit 99.1) for the full announcement but does not include specific operational guidance or strategic outlook within the text of the 8-K itself.
- Risks and Contingencies: The document contains standard forward-looking statements regarding future events, noting that actual results may differ materially due to inherent risks and uncertainties. The Company explicitly disclaims any obligation to update these forward-looking statements.
- Unusual Items: None reported beyond the standard terms of the underwriting agreement and the exercise of the over-allotment option.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received upon settlement on or after February 13, 2026.
- Confirm the total number of shares outstanding post-offering to assess dilution impact.
- Review the full text of the press release (Exhibit 99.1) for management's stated use of proceeds.
- Monitor subsequent filings for any changes to the underwriting agreement terms or closing conditions.